Related Experiment Videos
[Hepatitis, cholestasis and amineptine (author's transl)]
La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris
|December 18, 1981
Summary
Amineptine hydrochloride, a tricyclic antidepressant, can cause drug-induced hepatitis. Symptoms like jaundice and abnormal liver tests appeared after treatment, resolving within weeks of discontinuation.
Area of Science:
- Hepatology
- Clinical Pharmacology
- Toxicology
Background:
- Amineptine hydrochloride is a tricyclic antidepressant.
- Drug-induced liver injury (DILI) is a significant concern with various medications.
Observation:
- Eight cases of hepatitis linked to amineptine hydrochloride treatment were documented.
- Hepatitis symptoms, including jaundice and abnormal liver function tests, emerged between 16 to 75 days of treatment.
- Patients received cumulative oral doses ranging from 3.8 to 26 grams.
Findings:
- Hepatotoxicity presented with cholestasis and/or cytolysis.
- Four cases showed combined cholestasis and cytolysis.
- Two cases each exhibited isolated cholestasis or predominantly cytolysis.
- Clinical recovery occurred within 10-21 days post-amineptine withdrawal.
- Abnormalities in liver function tests persisted for 3-12 weeks.
Implications:
- Amineptine hydrochloride can induce significant liver injury.
- Potential mechanisms include direct toxicity, enzyme induction, or immunoallergic reactions.
- Further research is needed to elucidate the precise pathophysiology of amineptine-induced hepatitis.